HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio has reiterated a Buy rating on Beam Therapeutics (NASDAQ: BEAM) and maintained a price target of $80 for the stock.